268 Bibliografia [1] Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain: September 2020, Vol 161 (9): 1976-82 [2] World Health Organization: Cancer Pain Relief. WHO, Geneva, 1986 [3] Terapia del dolore in Oncologia. Sistema Nazionale Linee Guida ISS. Giugno 2022. [4] The 2008 Erice group. The 2008 Erice Statement toward a more Humanistic Oncology. J Ambul Care Manage. 2009;32:2528. [5] van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Prevalence of pain in patients withcancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-69 [6] Caraceni A, Shkodra M. Cancer Pain Assessment and Classification Cancers 2019, 11, 510; doi:10.3390 [7] Costardi D, Rozzini L, Costanzi C, Ghianda D, Franzoni S, Padovani A, Trabucchi M. The Italian version of the pain assessment in advanced dementia (PAINAID) scale. Archives of gerontology and geriatrics, 44 (2): 175-180, 2007 [8] Foley KM. Acute and Chronic cancer syndromes. In: Doyle D, Hanks G, Cherny N, Calman K eds Oxford Textbook of Palliative Medicine (III edition), Oxford University Press 2004: 298-316 [9] Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain. Consensusconference of an expert working group of the European Association for palliative care. Cancer 2002;94(3):832-9 [10] Agency for health care policy and research clinical practice guideline cancer pain management. Rockville, MD: US Department of Health and Human Services, 1994 [11] Zagonel V, Cavanna L, Cetto PL, et al. Medical oncologist’ss role in palliative care: the AIOM’s position. Tumori 2009;95(6):6524 [12] Magee DJ, Jhanji S, Poulogiannis G, et al. Nonsteroidal anti-inflammatory drugs and pain in cancer patient: a systematic review and reappraisal of the evidence. Br J Anaesth. 2019;123(2):e412-e423. [13] Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. Journal of Clinical Oncology 2016;34(5):436-42 [14] Klepstad P, Kaasa S, Borchgrevink PC.Starting step III opioids for moderate to severe pain in cancer patients: dose titration: a systematic review. Palliat Med 2011;25:424-30 [15] Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based reccomandations from EAPC. Lancet Oncol. 2012;13(2):e58-68 [16] FaisingerRL, Fairchild A, Nekolaichuk C, et al. Is pain intensity a predictor of the complexity of cancer pain management? Jclin Oncol. 2009;27(4):585-90 [17] McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opiod side effects in cancer-related and chronic noncancer pain: a systematuc review. J Pain 2003;4(5):231-56 [18] Associazione Italiana di Oncologia Medica (2014). Tumori dell'anziano. available from: https://www.aiom.it/linee-guida-aiom/ [19] Thoms J Smith, Symtom Management in the older adult2015update. Clin Geriatr Med 2015;31(2):155-175 [20] Pergolizzi J, Boger RH, Budd K et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international espert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287-313
RkJQdWJsaXNoZXIy ODUzNzk5